APONTIS PHARM. AG INH ON Logo
DE000A3CMGM5
A3CMGM
APPH.DE

APONTIS PHARM. AG INH ON

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, APONTIS PHARM. AG INH ON had revenue of €26.03m and net profit of €603.75k

(EUR) June 2025
YoY
Revenue 26.03m -
Gross profit 7.41m -
Net profit 603.75k -
EBITDA 1.53m -

Fundamentals

Metric Value
Market capitalization
€91.63m
Number of shares
8.33m
52-week high/low
€12.35 - €9.70
Dividends No
Beta
1.16
P/E ratio
121.55
PEG ratio
1.47
P/B ratio
2.95
P/S ratio
1.89

Company profile

Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.

Name
APONTIS PHARM. AG INH ON
CEO
Sascha Glanemann
Headquarters Monheim am Rhein,
Germany
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
11/05/2021
Employees 137

Ticker symbols

Exchange Symbol
XETRA
APPH.DE
Frankfurt
APPH.F
Düsseldorf
APPH.DU
München
APPH.MU
Hamburg
APPH.HM
🍪

Parqet  uses cookies. Learn more